LI
Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
$3.47 -4.41% (-$0.16)
1M -50.92%
Market Cap $4.88M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 16.22x
EV/FFO N/A
P/S N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 367.93%
Asset turnover 0.00x
ROIC 225.12%
Debt
10 /100
High Current ratio 1.12x
Int. coverage -291.82x
Debt/Equity 4.80x
Stability
37 /100
Moderate EPS volatility 79.63%
Profitable years 0
Beta 0.71x
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre LIMN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chris Kim
Employees
1
Headquarters
Cerritos